Leuphasyl, known by the INCI designation pentapeptide-18, is a five-amino-acid sequence used as a topical cosmetic ingredient rather than a drug. It belongs to the same category of neurotransmitter-inhibiting peptides as Argireline, and it is discussed here in terms of mechanism, evidence, and clinical application. It is regulated as a cosmetic ingredient and is not FDA approved as a drug.

The peptide acts as an enkephalin mimetic. It binds the delta opioid receptor on presynaptic nerve terminals, a receptor coupled to inhibitory G proteins. This is a different route from the SNARE-targeting peptides, so it works upstream of vesicle docking.

How it works

Receptor activation triggers G-protein subunit dissociation. The released subunits close voltage-gated calcium channels and open potassium channels, which holds the neuron at a more negative resting potential. Without calcium influx, synaptic vesicle fusion is reduced, so acetylcholine release into the neuromuscular junction is modulated rather than abolished. The effect is reversible. Lowered acetylcholine reduces muscle contraction intensity, and repeated application over weeks is associated with progressive smoothing of expression lines.

Comparison and synergy

Leuphasyl can be contrasted with related actives by their target step in the neuromuscular cascade. Botulinum toxin cleaves SNAP-25 for a complete, irreversible block. Argireline competes for SNARE assembly for a reversible partial block. Leuphasyl acts further upstream at the calcium channel. Because these mechanisms are independent, in vitro glutamate-release models reported additive effects: roughly 32 percent inhibition for Leuphasyl alone and about 57 percent when combined with Argireline, a value the source described as similar to botulinum toxin in that assay. The Argireline plus Leuphasyl combination is marketed under the trade name Argireline.

Evidence and limitations

Reported cosmetic studies identified roughly a 2 percent concentration as a threshold for measurable wrinkle reduction in the frontal and periorbital areas over a 60-day course. Safety data in the cited literature showed no cytotoxicity to fibroblasts or keratinocytes, negative genotoxicity, and no ocular irritation. The speaker also noted an emerging D-tyrosine-modified analog with anti-melanogenic, skin-brightening signals in skin models, while emphasizing that no human depigmentation trials exist. The body of evidence remains limited: no randomized controlled trials, no independent replication, no human pharmacokinetic or skin-penetration data, and no studies across diverse skin types.

Key clinical points

• Leuphasyl is pentapeptide-18, a topical cosmetic ingredient and not an FDA-approved drug.
• It modulates acetylcholine release via delta opioid receptor binding, closing calcium channels upstream of vesicle docking; the effect is reversible.
• Its mechanism is independent of SNARE-targeting actives, supporting additive results when combined with Argireline.
• Cosmetic studies suggest a 2 percent threshold concentration with wrinkle reduction around 28 to 35 percent over 60 days.
• Evidence is constrained: no randomized controlled trials, no independent replication, and no human pharmacokinetic or penetration data.